目次

Table of Content

1. Research Methodology

2. Introduction To KIF18A Targeting Therapies
2.1 Overview of Kinesin Family and KIF18A
2.2 History and Development

3. Scientific and Biological Background
3.1 Overview of KIF18A
3.2 Oncogenic Role and Therapeutic Rationale

4. Therapeutic Approaches Targeting KIF18A
4.1 Small Molecule Inhibitors
4.2 RNAi Based Strategies

5. KIF18A Targeting Therapies RandD Trends By Indication
5.1 Solid Tumors
5.2 Hematological Malignancies

6. KIF18A Targeting Therapies Combination Strategies By Drug Class

7. KIF18A Targeting Therapies Market Potential Overview
7.1 Current Scenario
7.2 Future RandD and Commercial Opportunities

8. KIF18A Targeting Therapies Development Technology Platforms

9. KIF18A Targeting Therapies Clinical Trials Overview
9.1 By Company
9.2 By Country
9.3 By Indication
9.4 By Phase
9.5 By Priority Status

10. KIF18A Targeting Therapies Clinical Trials Insight By Company, Indication and Phase
10.1 Research
10.2 Preclinical
10.3 Phase I
10.4 Phase I/II

11. KIF18A Targeting Therapies Market Dynamics
11.1 Drivers and Opportunities
11.2 Challenges and Restraints

12. Competitive Landscape
12.1 Accent Therapeutics
12.2 Amgen
12.3 Apeiron Therapeutics
12.4 Aurigene Oncology
12.5 Genhouse Bio
12.6 GeneScience Pharmaceuticals
12.7 Iambic Therapeutics
12.8 Innogate Pharma
12.9 Insilico Medicine
12.10 Satya Pharma
12.11 Tailor Bio
12.12 Volastra

List of Figures
Figure 2-1: Kinesin Family Overview
Figure 2-2: KIF18A - Overview
Figure 2-3: Discovery and Evolution of KIF18A Research
Figure 3-1: KIF18A - Role In Mitosis
Figure 3-2: KIF18A - Expression in Normal and Cancer Tissues
Figure 3-3: KIF18A as Therapeutic Target in Cancer
Figure 3-4: KIF18A - Synthetic Lethality Pathway
Figure 3-5: KIF18A as Prognostic Marker in Cancer
Figure 4-1: Small Molecule KIF18A Inhibitors - Mechanism of Action
Figure 4-2: RNAi-Mediated Silencing of KIF18A - Mechanism of Action
Figure 4-3: KIF18A RNAi - Effects on Tumor Cell Phenotypes
Figure 5-1: SOVI-2302 Phase 1 (NCT06084416) Study - Initiation and Completion Year
Figure 5-2: VLS-1488-2201 Phase 1/2 (NCT05902988) Study - Initiation and Completion Year
Figure 5-3: ATX-295-001 Phase 1/2 (NCT06799065) Study - Initiation and Completion Year
Figure 5-4: GH2616-101 Phase 1 (NCT06329206) Study - Initiation and Completion Year
Figure 5-5: KIF18A In Hematological Malignancies - Role and Therapeutic Opportunity
Figure 7-1: KIF18A Targeting Therapies - Future Opportunities
Figure 8-1: Chemistry42 - Insilico Medicine
Figure 8-2: CINtech Platform - Volastra Therapeutics
Figure 8-3: Unnamed Platform - Accent Therapeutics
Figure 8-4: Unnamed Platform - Tailor Bio
Figure 9-1: Global - KF18A Targeting Therapies Clinical Trials By Company, 2025
Figure 9-2: Global - KF18A Targeting Therapies Clinical Trials By Country, 2025
Figure 9-3: Global - KF18A Targeting Therapies Clinical Trials By Indication, 2025
Figure 9-4: Global - KF18A Targeting Therapies Clinical Trials By Phase, 2025
Figure 9-5: Global - KF18A Targeting Therapies Clinical Trials By Priority Status, 2025
Figure 11-1: KIF18A Targeting Therapies Market - Drivers and Opportunities
Figure 11-2: KIF18A Targeting Therapies Market - Challenges and Restraints

List of Tables
Table 6-1: KIF18A Targeting Therapy In Combination With Chemotherapy
Table 6-2: KIF18A Targeting Therapy In Combination With Immunotherapy
Table 6-3: KIF18A Targeting Therapy In Combination With Targeted Therapy